Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharmacy and Chemistry

Junbo Zhang¹  Hongmei Jia¹  Benjamin Guillet²  Shozo Furumoto³  Winnie Deuther-Conrad⁴  Emerson Bernardes⁵  Min Yang⁶  Beverley Ellis⁷  Peter Caravan⁸  Ming-Rong Zhang⁹  Ya-Yao Huang^1,10  Hua Zhu^1,11  Xing Yang^1,12  Zhaofei Liu^1,13  Lars Perk^1,14  Filippo Lodi^1,15  Hua Yang^1,16  Ralf Schirrmacher^1,17  Peter Laverman^1,17  R. Michael van Dam^1,18  Yubin Miao^1,19  Johnny Vercoullie^2,20  Zijing Li^2,21 

[1] Beijing Normal University;CERIMED, C2VN, Aix-Marseille Univ;CYRIC, Tohoku University;Helmholtz-Zentrum Dresden-Rossendorf (HZDR);IPEN;Jiangsu Institute of Nuclear Medicine;Manchester University NHS Foundation Trust;Massuchusetts General Hospital, Harvard University;NIRS;National Taiwan University College of Medicine;Peking University Cancer Hospital;Peking University First Hospital;Peking University;Radboud University Medical Center;S. Orsola-Malpighi Hospital;TRIUMF;University of Alberta;University of California, Los Angeles;University of Colorado;University of Tours;Xiamen University;

关键词: Highlights;    Radiopharmacy;    Radiochemistry;    Review;   

DOI  :  10.1186/s41181-022-00162-3

来源: DOAJ

【 摘 要 】

Abstract Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included. Conclusion Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

【 授权许可】

Unknown